Orlistat: A Repositioning Opportunity as a Growth Inhibitor of Apicomplexan Parasites?

Apicomplexan Parasites: Molecular Approaches toward Targeted Drug Development

Volumn , Issue , 2011, Pages 481-492

  Miculka, Christian ^a,b   Tran, Hon Q ^a   Selzer, Paul M ^a   Meyer, Thorsten ^a   Heckeroth, Anja R ^a   Baumeister, Stefan ^c   Seeber, Frank ^d  

^a Intervet Innovation GmbH   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Bioinformatics; Drug repositioning; Eimeria; Fatty acid synthetase; Lipase; Plasmodium; Toxoplasma; Xenical

Indexed keywords

EID: 79959796580     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527633883.ch26     Document Type: Chapter

References (59)

1. Ashburn, T.T. and Thor, K.B. (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Disc., 3, 673-683.
2. Stuart M. (2004) Rediscovering existing drugs. Start-Up, 9, 23-30.
3. Tobinick, E.L. (2009) The value of drug repositioning in the current pharmaceutical market. Drug News Perspect., 22, 119-125.
4. Geary, T.G.,Woods, D.J., Williams, T., and Nwaka, S. (2009) Target identification and mechanism-based screening for anthelmintics: application of veterinary antiparasitic research programs to search for new antiparasitic drugs for human indications, in Drug Discovery in Infectious Diseases. Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates (ed. P.M. Selzer), Wiley-VCH, Weinheim.
5. Pailet, F.A., Abadie, S.H., Smith, M.W., and Gonzalez, R.R. (1968) Chemotherapeutic heartworm control - the use of diethylcarbamine in the control of Dirofilaria immitis infection in dogs in clinical trials. Vet. Med. Sm. Anim. Clin., 63, 691-693.
6. McQuistion, T.E. and McDougald, L.R. (1981) Anticoccidial activity of arprinocid and halofuginone. Vet. Parasitol., 9, 27-33.
7. Villacorta, I., Peeters, J.E., Vanopdenbosch, E., Ares-Mazas, E., and Theys, H. (1991) Efficacy of halofuginone lactate against Cryptosporidium parvum in calves. Antimicrob. Agents Chemother., 35, 283-287.
8. Pines, M. and Nagler, A. (1998) Halofuginone: a novel antifibrotic therapy. Gen. Pharmacol., 30, 445-450.
9. Pines, M., Vlodavsky, I., and Nagler, A. (2000) Halofuginone: from veterinary use to human therapy. Drug Dev. Res., 50, 371-378.
10. Popov, Y. and Schuppan, D. (2009) Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology, 50, 1294-1306.
11. Hodges, S.J. (2008) Urologic devices incorporating collagen inhibitors. WO2008069961.
12. Sullivan, C.A. and Hodges, S.J. (2009) Medical devices incorporating collagen inhibitors. US20090028914.
13. Boettner A., Schmid, P., and Humke, R. (1995) In vitro efficacy of cefquinome (INN) and other anti-infective drugs against bovine bacterial isolates from Belgium, France, Germany, The Netherlands, and the United Kingdom. J. Vet. Med., Ser. B, 42, 377-383.
14. McCann, M.E., Andersen, D.R., Zhang, D., Brideau, C., Black, W.C., Hanson, P.D., and Hickey, G.J. (2004) In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. Am. J. Vet. Res., 65, 503-512.
15. Cavaliero, T., Arnold, P., Mathis, A., Glaus, T., Hofmann-Lehmann, R., and Deplazes, P. (1999) Clinical, serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum. J. Vet. Intern. Med., 13, 330-334.
16. Mateo, M., Maynard, L., Vischer, C., Bianciardi, P., and Miró, G. (2009) Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniasis. Parasitol. Res., 105, 155-162.
17. Goodman, C.D., Su, V., and McFadden, G.I. (2007) The effects of anti-bacterials on the malaria parasite Plasmodium falciparum. Mol. Biochem. Parasitol., 152, 181-191.
18. Ghedin, E., Hailemariam, T., DePasse, J.V., Zhang, X., Oksov, Y., Unnasch, T.R., and Lustigman, S. (2009) Brugia malayi gene expression in response to the targeting of theWolbachia endosymbiont by tetracycline treatment. PLoS Negl. Trop. Dis., 3, e525.
19. Kinnings, S.L., Liu, N., Buchmeier, N., Tonge, P.J., Xie, L., and Bourne, P.E. (2009) Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput. Biol., 5, e1000423.
20. Abdulla, M.-H., Ruelas, D.S., Wolff, B., Snedecor, J., Lim, K.-Ch., Xu, F., Renslo, A.R.,Williams, J.,McKerrow, J.H., and Caffrey, C.R. (2009) Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl. Trop. Dis., 3, e478.
21. Weisman, J.L., Liou, A.P., Shelat, A.A., Cohen, F.E., Guy, R.K., and DeRisi, J.L. (2006) Searching for new antimalarial therapeutics amongst known drugs. Chem. Biol. Drug Des., 67, 409-416.
22. Mackey, Z.B., Baca, A.M., Mallari, J.P., Apsel, B., Shelat, A., Hansell, E.J., Chiang, P.K., Wolff, B., Guy, K.R., Williams, J., and McKerrow, J.H. (2006) Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem. Biol. Drug Des., 67, 355-363.
23. Chiang, A.P. and Butte, A.J. (2009) Systematic evaluation of drug-disease relationships to identify leads for novel drug uses. Clin. Pharm. Ther., 86, 507-510.
24. Qu, X.A., Gudivada, R.C., Jegga, A.G., Neumann, E.K., and Aronow, B.J. (2009) Inferring novel disease indication for known drugs by semantically linking drug action and disease mechanism relationships. BMC Bioinform., 10 (Suppl. 5), S4.
25. Hadvary, P., Sidler, W., Meister, W., Vetter, W., and Wolfer, H. (1991) The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. J. Biol. Chem., 266, 2021-2027.
26. Kridel, S.J., Axelrod, F., Rozenkrantz, N., and Smith, J.W. (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res., 64, 2070-2075.
27. Hochuli, E., Kupfer, E., Maurer, R., Meister,W.,Mercadal, Y., and Schmidt, K. (1987) Lipstatin, an inhibitor of pancreatic lipase produced by Streptomyces toxytricini, I. Chemistry and structure elucidation. J. Antibiot., 40, 1086-1091.
28. Hadvary, P., Hochuli, E., Kupfer, E., Lengsfeld, H., and Weibel, E.K. (1985) Hexadecanoic acid and hexadecadienoic acid derivatives. EP129748.
29. Weibel, E.K., Hadvary, P., Hochuli, E., Kupfer, E., and Lengsfeld, H. (1987) Lipstatin, an inhibitor of pancreatic lipase produced by Streptomyces toxytricini, II. Producing organism, fermentation, isolation and biological activity. J. Antibiot., 40, 1081-1085.
30. Umezawa, H., Aoyagi, T., Hazato, T., Uotani, K., Kojima, F., Hamada, M., and Takeuchi, T. (1978) Esterastin, an inhibitor of esterase, produced by Actinomycetes. J. Antibiot., 31, 639-641.
31. Kitahara, M., Asano, M., Naganawara, H., Maeda, K., Hamada, M., Aoyagi, T., Umezawa, H., Itiaka, H.Y., and Nakamura, H. (1987) Valilactone, produced by Actinomycetes. J. Antibiot., 40, 1647-1650.
32. Mutoh, M., Nakada, N., Matsukuma, S., Ohshima, S., Yoshinari, K., Watanabe, J., and Arisawa, M. (1994) Panclicins, novel pancreatic lipase inhibitors. I. Taxonomy, fermentation, isolation and biological activity. J. Antibiot., 47, 1369-1375.
33. Barbier, P. and Schneider, F. (1987) Syntheses of tetrahydrolipstatin and absolute configuration of tetrahydrolipstatin and lipstatin. Helv. Chim. Acta, 70, 196-202.
34. Case-Green, S.C., Davies, S.G., Roberts, P.M., Russel, A.J., and Thomson, J.E. (2008) Asymmetric synthesis of tetrahydrolipstatin and valilactone. Tetrahedron: Asymm., 19, 2620-2631.
35. Srinivas, P.V., Aswathanarayanappa, C., Sannachikkanna, U., and Guptha, R. (2009) Process for preparation of tetrahydrolipstatin via hydrogenation of lipstatin in polyethylene glycol. WO2009040827.
36. Simonic, I., Kramar, A., Benkic, P., Simac, A., and Vajs, A. (2007) Process for preparing crystalline forms of orlistat. EP1803714.
37. Yadav, J.S., Reddy, M.S., and Prasad, A.R. (2006) Stereoselective synthesis of (-)-tetrahydrolipstatin via Prins cyclisations. Tetrahedron Lett., 47, 4995-4998.
38. Ghosh, A.K. and Fidanze, S. (2000) Asymmetric synthesis of (-)-tetrahydrolipstatin: An anti-aldolbased strategy. Org. Lett., 2, 2405-2407.
39. Hanessian, S., Tehim, A., and Chen, P. (1993) Total synthesis of (-)-tetrahydrolipstatin. J. Org. Chem., 58, 7768-7781.
40. Pons, J.-M. and Kocienski, P. (1989) A synthesis of (-)-tetrahydrolipstatin. Tetrahedron Lett., 30, 1833-1836.
41. Dirat, O., Kouklovsky, C., and Langlois, Y. (1999) OxazolineN-oxide-mediated [2 {thron}3] cycloadditions. Application to a synthesis of (-)-tetrahydrolipstatin. Org. Lett., 1, 753-755.
42. Barbier, P., Schneider, F., and Widmer, U. (1987) Stereoselective syntheses of tetrahydrolipstatin and of an analogue, potent pancreatic-lipase inhibitor containing a b-lactone moiety. Helv. Chim. Acta, 70, 1412-1418.
43. Leibundgut, M., Maier, T., Jenni, S., and Ban, N. (2008) The multienzyme architecture of eukaryotic fatty acid synthases. Curr. Opin. Struct. Biol., 18, 714-725.
44. Pemble, C.W., Johnson, L.C., Kridel, S.J., and Lowther,W.T. (2007) Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by orlistat. Nat. Struct. Mol. Biol., 14, 704-709.
45. Knowles, L.M., Axelrod, F., Browne, C.D., and Smith, J.W. (2004) A fatty acid synthase blockade induces tumor cellcycle arrest by down-regulating Skp2. J. Biol. Chem., 279, 30540-30545.
46. Knowles, L.M., Yang, C., Osterman, A., and Smith, J.W. (2008) Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4. J. Biol. Chem., 283, 31378-31384.
47. Surolia, A., Ramya, T.N., Ramya, V., and Surolia, N. (2004) 'FAS't inhibition of malaria. Biochem. J., 383, 401-412.
48. Mazumdar, J. and Striepen, B. (2007) Make it or take it: fatty acid metabolism of apicomplexan parasites. Eukaryot. Cell, 6, 1727-1735.
49. Goodman, C.D. and McFadden, G.I. (2008) Fatty acid synthesis in protozoan parasites: Unusual pathways and novel drug targets. Curr. Pharm. Des., 14, 901-916.
50. Omura, S. (1976) The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis. Microbiol. Mol. Biol. Rev., 40, 681-697.
51. Trager,W. and Jensen, J.B. (1976) Human malaria parasites in continuous culture. Science, 193, 673-675.
52. Roos, D.S., Donald, R.G., Morrissette, N.S., and Moulton, A.L. (1994) Molecular tools for genetic dissection of the protozoan parasite Toxoplasma gondii. Meth. Cell Biol., 45, 27-63.
53. Smilkstein, M., Sriwilaijaroen, N., Kelly, J.X., Wilairat, P., and Riscoe, M. (2004) Simple and inexpensive fluorescence-based technique for highthroughput antimalarial drug screening. Antimicrob. Agents Chemother., 48, 1803-1806.
54. Crawford, M.J., Thomsen-Zieger, N., Ray, M., Schachtner, J., Roos, D.S., and Seeber, F. (2006) Toxoplasma gondii scavenges host-derived lipoic acid despite its de novo synthesis in the apicoplast. EMBO J., 25, 3214-3222.
55. Yu, M., Kumar, T.R., Nkrumah, L.J., Coppi, A., Retzlaff, S., Li, C.D., Kelly, B.J., Moura, P.A., Lakshmanan, V., Freundlich, J.S., Valderramos, J.C., Vilcheze, C., Siedner, M., Tsai, J.H., Falkard, B., Sidhu, A.B., Purcell, L.A., Gratraud, P., Kremer, L., Waters, A.P., Schiehser, G., Jacobus, D.P., Janse, C.J., Ager, A., Jacobs, W.R. Jr, Sacchettini, J.C., Heussler, V., Sinnis, P., and Fidock, D.A. (2008) The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe., 11, 567-578.
56. Vaughan, A.M., O'Neill, M.T., Tarun, A.S., Camargo, N., Phuong, T.M., Aly, A.S., Cowman, A.F., and Kappe, S.H. (2009) Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell Microbiol., 11, 506-520.
57. Tarun, A., Vaughan, A., and Kappe, S. (2009) Redefining the role of de novo fatty acid synthesis in Plasmodium parasites. Trends Parasitol., 25, 545-550.
58. Mazumdar, J., Wilson, E.H., Masek, K., Hunter, C.A., and Striepen, B. (2006) Apicoplast fatty acid synthesis is essential for organelle biogenesis and parasite survival in Toxoplasma gondii. Proc. Natl Acad. Sci. USA, 103, 13192-13197.
59. Yang, P.Y., Liu, K., Ngai, M.H., Lear, M.J., Wenk, M.R., and Yao, S.Q. (2010) Activitybased proteome profiling of potential cellular targets of Orlistat-an FDAapproved drug with anti-tumor activities. J. Am. Chem. Soc., 132, 656-666.